Group 1 - The core viewpoint is that Fuhong Hanlin (02696) has seen a significant stock price increase of over 6% following the announcement of a stock option plan and restricted share unit plan, which requires shareholder approval [1] - The board of directors approved the conditional grant of a total of 6.985 million stock options and 698.5 restricted share units to 279 participants, including 75,000 stock options and restricted share units to CEO Dr. Zhu Jun [1] - Fuhong Hanlin's PD-L1 ADC (HLX43) has entered the international multi-center Phase II clinical study for advanced non-small cell lung cancer patients, marking it as the first PD-L1 ADC to enter Phase II clinical trials globally [1] Group 2 - CMB International highlights Fuhong Hanlin's potential to evolve from a profitable biosimilar company to a leading player in the biopharmaceutical sector, with promising clinical data for several innovative drugs including HLX43 and Serplulimab [2] - The target price for Fuhong Hanlin has been raised from HKD 20.33 to HKD 61.98, maintaining a "Buy" rating due to the company's strong commercial performance of its products and ongoing FDA reviews for HLX14 and HLX11 [2] - The company is actively expanding its global biosimilar business through partnerships with pharmaceutical companies, which is expected to enhance overseas revenue sources [2]
港股异动 | 复宏汉霖(02696)涨超6% 公司批准股权激励计划 机构指其创新药发展潜力庞大